-Reuters
Johnson & Johnson Unit Janssen Announced New STELARA Long-Term Data Support Its Established Safety Profile In Inflammatory Bowel Disease And Durable Efficacy In Ulcerative Colitis
he Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn's disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extensi
